KIT and cancer: Most imatinib-resistant cases have a secondary Kit mutation in the kinase domain, and then lose sensitivity to the drug.23, 26, 27 In other cancers with RTK(mut), resistance to TKIs develops in a manner similar to imatinib-resistant Kit.65 In this study, we showed that blockade of Kit trafficking from the ER suppresses its oncogenic signaling.